Claims
- 1. A compound of formula: ##STR5## wherein: R.sup.1 is H, --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3, or a caging group;
- R.sup.2 is H, --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3, or --P(O) (OR.sup.11) (X.sup.2 R.sup.12), or a caging group;
- R.sup.3 is H, --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3, --(O) (OR.sup.13) (X.sup.3 R.sup.14), or a caging group;
- R.sup.4 is H, --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3, --P(O) (OR.sup.15) (X.sup.4 R.sup.16), or a caging group;
- R.sup.5 is H, --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3, or a caging group;
- each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4, is, independently, S or O;
- each of R.sup.6, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 is, independently, H, --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, or --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3 ;
- each of R.sup.7 and R.sup.8 is, independently, a saturated or unsaturated C.sub.4 -C.sub.22 acyl, a C.sub.4 -C.sub.22 alkyl, a C.sub.4 -C.sub.22 alkenyl, or a C.sub.4 -C.sub.22 polyene.
- Z is O, CH.sub.2, or NH; and
- at least one of R.sup.6, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 is --CH.sub.2 OC(O)CH.sub.3, --CH.sub.2 OC(O)CH.sub.2 CH.sub.3, or --CH.sub.2 OC(O) (CH.sub.2).sub.2 CH.sub.3.
- 2. The compound of claim 1, wherein R.sup.2 is --P(O) (OR.sup.11) (X.sup.2 R.sup.12).
- 3. The compound of claim 1, wherein R.sup.3 is --P(O) (OR.sup.13) (X.sup.3 R.sup.14).
- 4. The compound of claim 2, wherein R.sup.3 is --P(O) (OR.sup.13) (X.sup.3 R.sup.14).
- 5. The compound of claim 1, wherein R.sup.4 is --P(O) (OR.sup.15) (X.sup.4 R.sup.16).
- 6. The compound of claim 3, wherein R.sup.4 is --P(O) (OR.sup.15) (X.sup.4 R.sup.16).
- 7. The compound of claim 4, wherein R.sup.4 is --P(O) (OR.sup.15) (X.sup.4 R.sup.16).
- 8. The compound of claim 1, wherein Z is O.
- 9. The compound of claim 1, wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is O.
- 10. The compound of claim 1, wherein the caging group is 2-nitrobenzyl, 1-(2-nitrophenyl)ethyl, 4,5-dimethoxy-2nitrobenzyl, 6-nitropiperonyl, 4-hydroxyphenacyl, or 7-hydroxycoumarin-4ylmethyl.
- 11. The compound of claim 1, wherein each of R.sup.7 and R.sup.8, independently, is --C(O) (CH.sub.2).sub.m CH.sub.3 where m is an integer between 4-20, inclusive, --C(O)--(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, --C(O)--(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 (CH.sub.3), --C(O)--(CH.sub.2).sub.7 CH.dbd.CHCH.sub.2 CH.dbd.CH (CH.sub.2).sub.4 CH.sub.3, or --C(O)--(CH.sub.2).sub.2 (CH.sub.2 CH.dbd.CH).sub.4 (CH.sub.2).sub.4 CH.sub.3, wherein each double bond independently, is in a cis or trans configuration.
- 12. The compound of claim 1, wherein each of R.sup.6, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 is --CH.sub.2 OC(O)CH.sub.3.
- 13. The compound of claim 1, wherein at least one of R.sup.2, R.sup.3, and R.sup.4 is a phosphorus-containing group.
- 14. The compound of claim 1, wherein at least two of R.sup.2, R.sup.3, and R.sup.4 are phosphorus-containing groups.
- 15. The compound of claim 1, wherein R.sup.2, R.sup.3, and R.sup.4 are phosphorus-containing groups.
- 16. A pharmaceutical composition of the compound of claim 1.
- 17. The compound of claim 1 of the formula: ##STR6##
- 18. The compound of claim 17, wherein R.sup.2 is --P(O) (OR.sup.11) (X.sup.2 R.sup.12).
- 19. The compound of claim 17, wherein R.sup.3 is --P(O) (OR.sup.13) (X.sup.3 R.sup.14).
- 20. The compound of claim 18, wherein R.sup.3 is --P(O) (OR.sup.13) (X.sup.3 R.sup.14).
- 21. The compound of claim 17, wherein R.sup.4 is --P(O) (OR.sup.15) (X.sup.4 R.sup.16).
- 22. The compound of claim 19, wherein R.sup.4 is --P(O) (OR.sup.15) (X.sup.4 R.sup.16).
- 23. The compound of claim 20, wherein R.sup.4 is --P(O) (OR.sup.15) (X.sup.4 R.sup.16).
- 24. The compound of claim 17, wherein Z is O.
- 25. The compound of claim 17, wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is O.
- 26. The compound of claim 17, wherein the caging group is 2-nitrobenzyl, 1-(2-nitrophenyl)ethyl, 4,5-dimethoxy-2-nitrobenzyl, 6-nitropiperonyl, 4-hydroxyphenacyl, or 7-hydroxycoumarin-4-ylmethyl.
- 27. The compound of claim 17, wherein each of R.sup.7 and R.sup.8, independently, is --C(O) (CH.sub.2).sub.m CH.sub.3 where m is an integer between 4-20, inclusive, --C(O)--(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, --C(O)--(CH.sub.2).sub.7 CH.dbd.CH (CH.sub.2).sub.7 CH.sub.3, --C(O)--CH.sub.2).sub.7 CH.dbd.CHCH.sub.2 CH.dbd.CH(CH.sub.2).sub.4 CH.sub.3, or --C(O)--(CH.sub.2).sub.2 (CH.sub.2 CH.dbd.CH).sub.4 (CH.sub.2).sub.4 CH.sub.3, wherein each double bond, independently, is in a cis or trans configuration.
- 28. The compound of claim 17, wherein each of R.sup.6, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 is --CH.sub.2 OC(O)CH.sub.3.
- 29. The compound of claim 17, wherein at least one of R.sup.2, R.sup.3, and R.sup.4 are phosphorus-containing groups.
- 30. The compound of claim 17, wherein at least two of R.sup.2, R.sup.3, and R.sup.4 are phosphorus-containing groups.
- 31. The compound of claim 17, wherein R.sup.2, R.sup.3, and R.sup.4 are phosphorus-containing groups.
- 32. A pharmaceutical composition of the compound of claim 17.
- 33. The compound of claim 1 of the formula
- 34. The compound of claim 33, wherein R.sup.4 is --P(O) (OR.sup.15 (X.sup.4 R.sup.16).
- 35. The compound of claim 33, wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is O.
- 36. The compound of claim 33, wherein the caging group is 2-nitrobenzyl, 1-(2-nitrophenyl)ethyl, 4,5-dimethoxy-2-nitrobenzyl, 6nitropiperonyl, 4-hydroxyphenacyl, or 7-hydroxycoumarin-4-ylmethyl.
- 37. The compound of claim 33, wherein each of R.sup.7 and R.sup.8, independently, is --C(O) (CH.sub.2).sub.m CH.sub.3 where m is an integer between 4-20, inclusive, --C(O)--(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, --C(O)--(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, --C(O)--(CH.sub.2).sub.7 CH.dbd.CHCH.sub.2 CH.dbd.CH (CH.sub.2).sub.4 CH.sub.3, or --C(O)--(CH.sub.2).sub.2 (CH.sub.2 CH.sub.2 CH.dbd.CH).sub.4 (CH.sub.2).sub.4 CH.sub.3, wherein each double bond, independently, is in a cis or trans configuration.
- 38. The compound of claim 33, wherein each of R.sup.6, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 is --CH.sub.2 OC(O)CH.sub.3.
- 39. A pharmaceutical composition of the compound of claim 33.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
This invention was made with Government support under Grant (or Contract) No. NS27177, awarded by the National Institutes of Health. The Government has certain rights in this invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5866548 |
Tsien et al. |
Feb 1999 |
|